Resources

Sharing knowledge about promising practices and their sustainable implementation is vital to ending the opioid crisis. Our resources include the recommendations of experts and the perspectives of those on the frontlines.

COVID-19

SAMHSA: FAQ on the provision of methadone and buprenorphine for the treatment of OUD in the COVID-19 Emergency

March 19, 2020

The Substance Abuse and Mental Health Services Administration (SAMHSA) has compiled an FAQ on prescribing MOUD during the COVID-19 pandemic.

arrow-icn

COVID-19

SAMHSA: Opioid Treatment Program (OTP) Guidance

March 17, 2020

The Substance Abuse and Mental Health Services Administration (SAMHSA) expands previous guidance to provide increased flexibility during the COVID-19 pandemic and affirms its commitment to supporting OTPs in any way possible during this time.

arrow-icn

COVID-19

DEA: Expanded MOUD Telemedicine Guidance

March 17, 2020

The Drug Enforcement Administration (DEA) has provided further guidance on the expanded use of telemedicine for medications for opioid use disorder (MOUD) services during the COVID-19 national emergency.

arrow-icn

COVID-19

HHS/OCR: Enforcement Discretion for Telehealth Remote Communications During COVID-19

March 17, 2020

The Office for Civil Rights (OCR) will exercise enforcement discretion and will waive potential penalties for HIPAA violations against health care providers that serve patients through everyday communications technologies during the COVID-19 emergency.

arrow-icn

COVID-19

CA Bridge: MOUD and COVID-19 National Emergency Response

March 16, 2020

Guidance on how medications for opioid use disorder (MOUD) services must take immediate action to care for OUD patients while also slowing COVID-19 spread by implementing social distancing into all aspects of care.

arrow-icn

COVID-19

SAMHSA: COVID-19 Guidance for Opioid Treatment Programs

March 16, 2020

The Substance Abuse and Mental Health Services Administration (SAMHSA) provides guidance on pharmacotherapy for opioid use disorder availability in circumstances in which patients may be exposed to highly contagious infectious agents (such as COVID-19).

arrow-icn